Newsletter
Contact
Careers
Calendar
RFP
Français
myGAVI
Donate
Home
About the Alliance
Learn more about GAVI
GAVI's mission
What we do
GAVI's impact
Challenges and opportunities
Healthy girls, healthy women
Gender and immunisation
Why invest in GAVI?
Advocates
GAVI's strategy
Value of vaccination
GAVI's partnership model
GAVI's business model
Global health and development
Governing GAVI
GAVI Board
GAVI Secretariat
GAVI Internal Audit
Programmatic and Finance Policies
Corporate Policies
Types of support
What GAVI offers and how it works
Apply for support
New and underused vaccines support
Human papillomavirus vaccine
Injection safety support
Measles second dose
Meningitis A vaccine
Pentavalent vaccine
Pneumococcal vaccine
Measles-Rubella vaccine
Rotavirus vaccine
Yellow fever vaccine
Immunisation services support
Health Systems Funding Platform
Health system strengthening
Civil society organisation
Country hub
Afghanistan
Albania
Angola
Armenia
Azerbaijan
Bangladesh
Benin
Bhutan
Bolivia
Bosnia & Herzegovina
Burkina Faso
Burundi
Cambodia
Cameroon
Central African Republic (the)
Chad
China
Comoros
Congo
Congo, DR
Côte d’Ivoire
Cuba
Djibouti
Eritrea
Ethiopia
Gambia
Georgia
Ghana
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
India
Indonesia
Kenya
Kiribati
Korea, DPR
Kyrgyzstan
Lao PDR
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Moldova
Mongolia
Mozambique
Myanmar
Nepal
Nicaragua
Niger
Nigeria
Pakistan
Papua New Guinea
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
Solomon Islands
Somalia
South Sudan
Sri Lanka
Sudan
Tajikistan
Tanzania, UR
Timor Leste
Togo
Turkmenistan
Uganda
Ukraine
Uzbekistan
Vietnam
Yemen
Zambia
Zimbabwe
Funding & finance
Long-term financial commitments
How GAVI is funded
Key figures: donor contributions & pledges
Donor profiles
Financial reports
GAVI Matching Fund
How it works
Partners
International Finance Facility for Immunisation
Pneumococcal AMC
Results & evidence
Measuring & evaluating performance
Goal-level indicators
Mission indicators
Vaccine goal indicators
Health systems goal indicators
Financing goal indicators
Market-shaping goal indicators
Countries approved for support
Disbursements by country
GAVI's evaluation studies
GAVI first evaluation report
GAVI second evaluation report
GAVI support to CSO evaluation
GAVI-Government of China Hepatitis B vaccination programme
Gender Policy evaluation
IFFIm evaluation
Pneumococcal AMC process and design
Other studies
GAVI Progress reports
Library & news
Search by topic, country and programme
News
Press releases
Statements
Return on investment stories
GAVI features
Eyewitness
GAVI blogs
Audio-visual
Board & committee minutes
GAVI documents
Country documents
Evaluations
Financial reports
Guidelines and forms
Policies
Strategy
Supply and procurement
Publications
Events
You are here:
Library
Audio-visual
Audio-visual
Galleries
Galleries
Chad’s campaign against meningitis A
Chad’s campaign against meningitis A
in page functions
One of the first countries to introduce the new meningitis A vaccine (MenAfriVac), Chad ran an immunisation campaign with GAVI support in December 2011 to help eliminate the region’s devastating epidemics.
26 January 2012
UNICEF Chad/2011/Negrete
A young boy receives immunisation at a hospital in N’Djamena with a new vaccine against meningitis A -- one of up to 22 million people covered in the December 2011 campaign which also included northern Nigeria and Cameroon.
PATH/David Simpson
Chad lies at the centre of Africa’s so-called “meningitis belt” of 22 sub-Saharan countries, stretching from Senegal to Ethiopia. It is also one of the countries worst-affected by the regular meningitis epidemics that arrive on the hot seasonal winds, bringing death, disability, and fear.
UNICEF Chad/2011/Negrete
The new vaccine, MenAfriVac, is expected to dramatically reduce the impact of this terrible disease, saving as many as 150,000 lives by 2015. Developed in just 10 years, the new single-dose vaccine protects against meningitis A, the region’s most common form of meningitis.
UNICEF Chad/2011/Negrete
Actors present a sketch that highlights the benefits of immunisation against meningitis in N’Djamena. The region’s biggest epidemic in recent years affected 250,000 people, killing 25,000 and leaving another 50,000 with disabilities ranging from deafness to mental retardation.
UNICEF Chad/2011/Negrete
Social mobiliser Ali Abakar (left) and public crier Moussa Alhat (right) spread the word about the meningitis A vaccine campaign. Imams and teachers also played a lead role in social mobilisation throughout the region.
UNICEF Chad/2011/Negrete
Three-year old Melomegoto receives her immunisation shot at the Am Toukoui Health Centre in N’Djamena. GAVI has allocated US$ 370.4 million to ensure that the vaccine reaches as many as 500 million people such as Melomegoto who live in the “meningitis belt”.
UNICEF Chad/2011/Negrete
Initial results from the 2010 campaigns in Burkina Faso, Mali, and Niger, which also delivered the new MenAfriVac vaccine, have been excellent. Burkina Faso had just four cases of meningitis in the 2011 epidemic season, all in unimmunised individuals.
Latest Galleries
Launch ceremony for introduction of pentavalent vaccine - Mogadishu, Somalia
Immunisation in Islamic countries
Madagascar celebrates the introduction of pneumococcal vaccines
Brazzaville marks Congo's first pneumococcal vaccinations
Rotavirus vaccines introduced in health centres in Yemen
The human tragedy and the hope behind Ghana’s historic decision
Model immunisation system sets standard for Mozambique
Seth Berkley in Mozambique March 2012
Chad’s campaign against meningitis A
GAVI’s Matching Fund announcement at WEF
View all latest galleries
Related Library items
100 millionth person receives lifesaving meningitis vaccine
GAVI partners help protect 50 million young people from seasonal meningitis in Africa
Q and A on Nigeria’s introduction of MenAfriVac
Related information
Meningitis A vaccine support
GAVI blogs
Disbursements by country
modal window here